Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2021-11-24 00:00:00 ET · period of report 2021-11-22 · accession 0001209191-21-066795 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-24 | 2021-11-22 | PCRX | LARANJEIRA CHARLES ANTHONY | Chief Technical Off | M - OptEx | $44.10 | +7,500 | 33.6K | +29% | +$330.8K |
| D | 2021-11-24 | 2021-11-22 | PCRX | LARANJEIRA CHARLES ANTHONY | Chief Technical Off | M - OptEx | $0.00 | -7,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-22 | M | A | 7,500 | $44.10 | 33,602 | D | — | — | (F1) Includes 421 shares of common stock acquired under the issuer's employee stock purchase plan in June 2021. |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-11-22 | M | D | 7,500 | $0.00 | 0 | D | $44.10 · — to 2027-06-02 | 7,500 Common Stock | (F2) The stock option vested and became exercisable as to 25% of the option shares on May 1, 2018, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. |